Abstract

The fixed-dose combination elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF) is a first-line agent for the treatment of human immunodeficiency virus (HIV) infection. We report the case of a 25-year-old man with newly diagnosed HIV infection who was treated with E/C/F/TAF. The patient's hepatitis panel results were negative. Neither illicit drug abuse nor hepatotoxic medication was reported. Significantly elevated alanine aminotransferase with jaundice was found in the fourth week during the treatment course. His liver function gradually improved after withdrawal of the medication. This is the first report to our knowledge of E/C/F/TAF-related acute hepatitis.